10 recruiting, 5 terminated, 3 active not recruiting, 2 completed. 14 Phase 2, 13 Phase 1, 1 Early Phase 1.
Follow tagraxofusp: new trials by email Literature Review of tagraxofusp trials Research Report on tagraxofusp
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients Venetoclax, Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2025-12-11 | 2026-07-01 |
| Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined Tagraxofusp, Pacritinib - Myelofibrosis，MF | Early Phase 1 | Recruiting | University of Kansas Medical Center | 20 | 2025-08-25 | 2026-05-06 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Tagraxofusp, Cladribine (CLAD), Cytarabine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Stanford University | 20 | 2025-02-10 | 2026-04-14 |
| Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | City of Hope Medical Center | 43 | 2025-01-28 | 2026-07-16 |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy Tagraxofusp, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Stemline Therapeutics, Inc. | 85 | 2025-01-14 | 2026-08-06 |
| Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia Azacitidine, Tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-08-03 | 2024-03-08 | |
| A Registry-study of ELZONRIS in Participants With BPDCN Tagraxofusp - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | Stemline Therapeutics, Inc. | 80 | 2024-06-26 | 2026-08-25 | |
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents Tagraxofusp, Azacitidine, Venetoclax - Acute Myeloid Leukemia | Phase 2 | Recruiting | Joshua Zeidner | 53 | 2024-05-01 | 2026-07-10 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) Tagraxofusp - Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1 | Active not recruiting | Karen Ballen, MD | 44 | 2022-07-13 | 2026-07-16 |
| Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes Decitabine, Tagraxofusp-erzs - Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 64 | 2022-03-04 | 2026-07-14 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia tagraxofusp - Acute Myeloid Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 25 | 2021-02-16 | 2025-01-30 |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Cyclophosphamide, Cytarabine, Dexamethasone - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-05-29 | 2026-09-14 |
| Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant Tagraxofusp-erzs - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2020-03-27 | 2024-07-31 |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Azacitidine, SL-401, Venetoclax - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 72 | 2017-06-26 | 2026-06-17 |
| Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Tagraxofusp Injection - Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Completed | Stemline Therapeutics, Inc. | 82 | 2016-02-10 | 2025-01-06 |
| SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma SL-401 7 µg/kg/day, SL-401 9 µg/kg/day - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Stemline Therapeutics, Inc. | 9 | 2016-01-01 | 2024-04-17 |
| SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission Tagraxofusp-erzs - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Stemline Therapeutics, Inc. | 16 | 2015-02-01 | 2024-10-17 |
Showing 20 of 21. Sign in to see all of them.
Leukemia, Myeloid, Acute (11) · Blastic Plasmacytoid Dendritic Cell Neoplasm (7) · Leukemia, Myelomonocytic, Chronic (3) · Primary Myelofibrosis (3) · Hematologic Neoplasms (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Multiple Myeloma (1)
Stemline Therapeutics, Inc. (6) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · French Innovative Leukemia Organisation (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Jacqueline Garcia, MD (1) · Jonsson Comprehensive Cancer Center (1) · Joshua Zeidner (1) · Karen Ballen, MD (1) · Stanford University (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · University of Kansas Medical Center (1)
United States (18) · Australia (2) · Italy (2) · Austria (1) · Canada (1) · France (1) · Germany (1) · Switzerland (1)
Abdulraheem Yacoub, Doctor of Medicine (1) · Adam Lamble, MD (1) · Andrew Lane, MD, PhD (1) · Caspian Oliai, MD (1) · Guillermo M Bravo, MD (1) · Jacqueline Garcia, MD (1) · Joshua Zeidner, MD (1) · Karen Ballen (1) · Naveen Pemmaraju (1) · Nicholas Short, MD (1) · Qaiser Bashir, MS (1)
PMID 33795208, PMID 31018069, PMID 35820082, PMID 38052038, PMID 40919483, PMID 41146971, PMID 41486505
P30CA016672 (1), P30CA033572 (1)